Answers are grounded in this paper and cite their sources.
In this real-world cohort, SVR rates were lower than in clinical trials. Genotype 1 and 2 HCV-infected patients with advanced liver disease by APRI >2 or FIB-4 > 3.25 were significantly less likely to achieve SVR. For genotype 1, a SOF + SIM ± RBV regimen was associated with a higher likelihood of SVR.
No takes yet. Share an insight, caveat, or question.
Backus et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: